Key Takeaways
- •Aviptadil acetate serves as the generic name for a synthetic form of vasoactive intestinal peptide, consisting of 28 amino acids.
- •Idiopathic PAH patients show a deficiency in VIP, which leads to increased expression of receptors in the pulmonary vasc
- •PAH therapy includes various drugs, yet gaps remain in effectiveness.
Aviptadil Acetate as a Synthetic VIP
Aviptadil acetate serves as the generic name for a synthetic form of vasoactive intestinal peptide, consisting of 28 amino acids. Researchers have examined this peptide for its effects on pulmonary arterial hypertension, a condition marked by increased pulmonary vascular resistance and elevated pulmonary arterial pressure due to narrowing of the arterial lumens. Current PAH treatments face several limitations, prompting tests of small molecule drugs and peptides, including inhaled aviptadil for idiopathic PAH.
Idiopathic PAH patients show a deficiency in VIP, which leads to increased expression of receptors in the pulmonary vasculature as a counterbalance.
Challenges in PAH and Need for New Options
PAH therapy includes various drugs, yet gaps remain in effectiveness. Inhalation of aviptadil emerges as a potential method to address idiopathic PAH, where VIP levels are low. This approach aims to leverage the peptide's properties to improve vascular function.
For details on peptides like VIP, consult the Peptide Glossary.
Acute Effects from Inhaled Aviptadil Doses
One study assessed a single 100-mg inhaled dose of aviptadil in patients with moderate to severe PAH, measuring impacts on hemodynamics, blood gases, and tolerability. The treatment proved well tolerated, functioning as a mild vasodilator selective to the pulmonary system and reducing strain on the right heart. These outcomes appeared similar between PAH patients and those without PAH.
Aviptadil also showed a tendency to enhance oxygenation in individuals with chronic lung disease, indicating a need for more research on its therapeutic value in PAH.
In another acute test during right heart catheterization, a single 100 μg dose in eight idiopathic PAH patients reduced pulmonary artery pressure by 10 mmHg and raised cardiac output by 0.8 L/min.
Chronic Treatment Outcomes
Chronic administration involved four daily inhalations totaling 200 μg per day over 12 weeks in idiopathic PAH patients. This regimen led to notable gains in the 6-minute walk test distance. While vasodilation effects were not as pronounced as in some acute settings, cardiac output rose by about 0.6 L/min in the PAH group.
Researchers note that the limited relaxation from a single 100 μg dose might not capture the compound's complete potential.
Phase I trials reported significant improvements in patients' exercise capacity after three to six months of aviptadil treatment.
Planning peptide cycles? Use our Dosage & Cycle Planner for research guidance.
Role of VIP in Pulmonary Vascular Processes
Evidence points to VIP's involvement in controlling proliferation of smooth muscle cells in pulmonary blood vessels. VIP deficiency results in moderately severe PAH, as seen in male mice genetically lacking the VIP gene. This finding supports the idea that ongoing aviptadil treatment could aid in reversing vascular remodeling in PAH.
Key Studies on Aviptadil and VIP
Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., and Stiebellehner, L. (2003). 'Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension’, Journal of Clinical Investigation, 111(9): 1339-1346.
Said, S.I., Hamidi. S.A., Dickman, K.G.,Szema, A. M., Lyubsky, S. (2007). 'Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene’, Circulation, 115(10): 1260-1268.
Leuchte, H.H., Baezner, C., Baumgartner, R. A., Bevec, D. Bacher, G. (2008). 'Inhalation of vasoactive intestinal peptide in pulmonary hypertension’, European Respiratory Journal, 32(5): 1289-1294.
Summary of Findings
Aviptadil acetate demonstrates tolerability and benefits in PAH through vasodilation, cardiac output gains, and exercise improvements. Mouse models reinforce VIP's protective role against vascular changes. These results call for continued research into its clinical applications.
Explore more with our Free peptide tools.